Toxicology Excellence for Risk Assessment Perchlorate Data Gaps Joan Dollarhide, M.S., MSTC, J.D. Toxicology Excellence for Risk Assessment (TERA)

Slides:



Advertisements
Similar presentations
Mechanisms of Thyroid Toxicity Kevin M. Crofton Neurotoxicology Division National Health and Environmental Effects Laboratory US Environmental Protection.
Advertisements

Trichloroethylene (TCE) Toxicity Values Update Waste Site Cleanup Advisory Committee Meeting March 27, 2014 C. Mark Smith Ph.D., M.S. Deputy Director Office.
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Chemical Carcinogens – workplace risk assessment and health surveillance Tiina Santonen Paide.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
1 David Loschke18 March 2005 New Zealand Timber Preservation Council Annual Conference 2005 The Australian Pesticides & Veterinary Medicines Authority.
CE 510 Hazardous Waste Engineering
1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.
Lynne Haber Toxicology Excellence for Risk Assessment Presentation to the CPSC April 8,
PCBs in Schools Risk e Learning Webinar April 28, Evaluating Health Risks from Inhaled PCBs: Research Needs to Address Uncertainty Geniece M. Lehmann,
Environmental Perchlorate Exposure and Human Health: from Newborn to Cancer.
Principles of Occupational Toxicology 2 – Types of toxicity
6/14/2012FDA/CVM 1 Tong Zhou, Ph.D., DABT Division of Human Food Safety Office of New Animal Drug Evaluation Center for Veterinary Medicine US Food and.
William H. Farland, Ph.D. Acting Deputy Assistant Administrator for Science Office of Research and Development U.S. ENVIRONMENTAL PROTECTION AGENCY Biomarkers:
Exposure Assessment Thanks to Marc Rigas, PhD for an earlier version of this lecture Much of the materials is drawn from Paustenbach, DJ. (2000) The practice.
Early programming hypothesis Wilfried Karmaus Reproductive Epidemiology EPI 824.
Environmental Health II. Toxicology Shu-Chi Chang, Ph.D., P.E., P.A. Assistant Professor 1 and Division Chief 2 1 Department of Environmental Engineering.
Michael H. Dong MPH, DrPA, PhD  readings Toxicology and Risk Assessment (3rd of 10 Lectures on Toxicologic Epidemiology)
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
Toxicology Excellence for Risk Assessment is a non-profit 501(c)(3) corporation dedicated to the best use of toxicity data for risk assessment.
Guidance for Industry M4S: The CTD-Safety
ILSI Risk Science Institute Acrylamide Toxicity: Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute.
Toxicology Component of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.
Committee on Carcinogenicity (COC) Approach to Risk Assessment of Genotoxic Carcinogens David H. Phillips* COC Chairman Descriptive vs. Quantitative.
Office of Pesticide Programs 21st Century Screening Assessment of Pesticides – A Regulatory View Vicki Dellarco, Ph.D. Senior Science Advisor Office of.
28/05/12 Questions (Rispondete alle domande che seguono usando il colore rosso per il testo) Tossicologia - Rubbiani Maristella.
TRAINING FOR THE HEALTH SECTOR
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Development, QA/QC and Status of Study Protocols David R. Mattie, PhD, DABT Operational Toxicology Branch AFRL/HEST Perchlorate Stakeholders Forum Sponsored.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 01 - INTRODUCTION.
Chapter 15 Environmental Health, Pollution and Toxicology.
Chapter 15 Environmental Health, Pollution and Toxicology.
TOXICOLOGY Trina Redford, Industrial Hygienist National Naval Medical Center Naval Business Bldg 615, 2 nd Fl. Philadelphia, PA.
Kevin M. Crofton, PhD US Environmental Protection Agency McKim Conference Duluth MN September 17, 2008 Thyroid Mediated CNS Dysfunction How to use what.
Overview of Lovastatin Nonclinical Developmental Data Karen Davis-Bruno; PhD Supervisory Pharmacologist Division of Metabolic & Endocrine Drugs NDAC/EMDAC.
Furan in Food Summary and Charge to the FAC and SCNT Terry C. Troxell, Ph.D. Director Office of Plant and Dairy Foods FDA Center for Food Safety and Applied.
2 n McKim Workshop on Reducing Data Redundancy in Cancer Assessment | 8 – 10 May 2012 | Baltimore, MD Highlighting the Need for AOPs in Streamlining Hazard.
Limitations of Current Toxicity Testing for Identifying Early Life Stage Susceptibilities Gary Ginsberg Connecticut Dept of Public Health NE SRA Regional.
Juan Alguacil, MD Huelva University Brussels, 26 June 2012 Limits on Occupational Exposure Limits for Carcinogens 8th Seminar on workers’ protection &
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
Prof. Dr. Wolfgang Dekant Department of Toxicology University of Würzburg Germany Risk, Hazard, and Innovation.
Toxicity and Risk Assessment of Perchlorate from a DoD Perspective David R. Mattie, PhD, DABT Senior Research Toxicologist Air Force Research Laboratory.
Pollution and Human Health
PRINCIPLES OF TOXICOLOGY...a discussion of the fundamental means by which toxicological properties are determined.
NUATRC/TCEQ Air Toxics Workshop October Air Toxics Air Toxics: What We Know, What we Don’t Know, and What We Need to Know Human Health Effects –
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 16-18, 2008 Toxicity Pathways as an Organizing Concept Gilman.
Case Study # 2  Problem Formulation  Inter-individual variability in cancer assessment (evaluate default from Silver Book)  Proposed Methods  Critical.
European Patients’ Academy on Therapeutic Innovation Non-clinical development.
‘DOSE’-‘OUTCOME’ IN GENERAL Relationship between a measured outcome associated with a measured dose –‘outcome’ = level of biological response or prevalence.
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 25-27, 2007 Toxicity Pathways as an Organizing Concept Gilman.
Innovative Modeling Approaches Applicable to Risk Assessments Thomas P. Oscar, PhD USDA, ARS Princess Anne, MD, USA.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.
Office of Research and Development National Center for Environmental Assessment Human Health Risk Assessment and Information for SRP July 28, 2009 Reeder.
The Environment and Human Health
Dose-Response and Critical Window Dioxins, Furans and PCBs - Hearing Loss Exposure Hepatic Phase II Enzymes Hepatic Parent or Metabolite  Serum T4 &
Anti thyroid medications Anti thyroid medications Nuwan Gunapala Registrar WD 21/40B.
Susan Makris USEPA, National Center for Environmental Assessment Washington, DC.
Acute Toxicity Studies Single dose - rat, mouse (5/sex/dose), dog, monkey (1/sex/dose) 14 day observation In-life observations (body wt., food consumption,
Human Health and Environmental Toxicology Chapter 7.
Emerging Methods for Controlling Chemicals E. Donald Elliott Professor (adj) of Law, Yale Law School Gail Charnley Elliott PhD.
DOSE-RESPONSE ASSESSMENT
Drug Candidate-Induced Changes in the Thyroid Gland: Contrasting Case Studies Joan Lane, Katie Zokowski, Jeffrey Horrigan, Daniel Aleksandrowicz, Doriana.
Susan Makris U.S. EPA, Office of Research and Development
ITER & RiskIE Databases
Pollution and Human Health
PESTICIDES AND CHILDREN as a Susceptible Population
Epidemiology and Toxicology of Disinfection By-Products
Presentation transcript:

Toxicology Excellence for Risk Assessment Perchlorate Data Gaps Joan Dollarhide, M.S., MSTC, J.D. Toxicology Excellence for Risk Assessment (TERA)

Toxicology Excellence for Risk Assessment Original Database Human Studies n Graves disease patients n Healthy volunteers Animal Studies n Less than 90 days n Cancer bioassays n Limited developmental/reproductive

Toxicology Excellence for Risk Assessment Original Data Gaps Studies needed to complete database: n at least subchronic bioassay n two-generation reproductive study n developmental toxicity studies in two species

Toxicology Excellence for Risk Assessment Studies to identify critical effect or reduce uncertainty: n developmental neurotoxicity study n genotoxicity study n immunotoxicity study

Toxicology Excellence for Risk Assessment Other major unanswered questions: n shape of dose-response curve in humans n effects from long-term exposure n effects in organs/systems other than thyroid n more complete understanding of kinetics and mechanism

Toxicology Excellence for Risk Assessment First Round of Studies n 90-day subchronic oral bioassay n Two-generation reproductive toxicity n Developmental toxicity in one species n Neurobehavioral developmental n Genotoxicity n Immunotoxicity n PBPK

Toxicology Excellence for Risk Assessment Remaining Data Gaps Studies needed to complete database: n developmental toxicity studies in a second species Studies to identify critical effect or reduce uncertainty: n establish separate dose-response curves for thyroid hypertrophy and hyperplasia n predictive immunotoxicity study

Toxicology Excellence for Risk Assessment Other major unanswered questions: n If dam is hypothyroid at time of conception, what are effects on fetal/neonatal thyroid and neurological development? n Is perchlorate transferred to pup via milk? n How do serum hormone levels correlate with thyroid pathology and neurohistopathology (fetal only)?

Toxicology Excellence for Risk Assessment n What is the effect of perchlorate on fetal/neonatal mental development? n What is shape of dose-response curve in humans?

Toxicology Excellence for Risk Assessment Second Round of Studies n PWG reevaluation of all thyroid histopathology n Predictive immunotoxicity studies n Developmental toxicity study in rats n “Effects study” n Motor activity study n Epidemiology and clinical human studies n PBPK modeling

Toxicology Excellence for Risk Assessment Remaining Data Gaps Studies needed to complete database: n none Studies to identify critical effect or reduce uncertainty: n host resistance assay n explore use of data-derived uncertainty factors following IPCS guidelines

Toxicology Excellence for Risk Assessment Other major unanswered questions: n How do we better integrate the existing human and animal data? n How do thyroid hormones fluctuate over time in animals and how do we explain some seemingly inconsistent findings in the animal studies?

Toxicology Excellence for Risk Assessment n How do we define the breakdown of normal thyroid homeostasis and progression to adversity? n Have we established dose-response curves for this process?

Toxicology Excellence for Risk Assessment Information and Status of Perchlorate Studies